Navigation Links
Point-of-Sale Electronic Safety Check May Reduce Heart Attack Risk for Diabetic Patients
Date:4/12/2011

ST. PAUL, Minn., April 12, 2011 /PRNewswire/ -- According to a new pharmacy benefit study, a point-of-sale automated electronic safety edit, designed to require provider prior authorization (PA) for members who have a rosiglitazone claim with concurrent use of insulin or nitrate (CIN), potentially decreased members' risk for myocardial ischemia. The study will be presented at the Academy of Managed Care Pharmacy's 23rd Annual Meeting in Minneapolis, Minn. by Prime Therapeutics (Prime), a thought leader in pharmacy benefit management.

Rosiglitazone, also known under its brand name Avandia®, is an antidiabetic drug therapy (ADT) designed to help control blood sugar in patients with Type 2 diabetes mellitus. Studies suggest rosiglitazone and CIN can put patients at an increased risk for myocardial ischemia, a condition where the arteries in the heart become blocked, thus increasing a person's risk for heart attack.

To prevent use of rosiglitazone and CIN, one of Prime's Blue Cross and Blue Shield (BCBS) clients implemented an automated electronic safety edit that included 1.2 million members. The edit required a PA for rosiglitazone if a CIN drug supply already existed.

During the six-month study period (Jan-Jun 2009), 168 members had their rosiglitazone claim denied at the point-of-sale. Researchers conducted an observational cohort study to assess ADT utilization in the 168 members in which a rosiglitazone claim was denied. Researchers also assessed a control group of 222 members for whom the safety edit was inactive. Claims for both groups were periodically observed post-denial, or post-initial paid rosiglitazone claim among control group, to determine whether members continued with rosiglitazone, switched to a safer alternative or abandoned therapy altogether.

After 180 days, 78.6 percent of the 168 members with an initial safety edit claim denial were using a different ADT other than rosiglitazone, versus only 25.6 percent of control group. The safety edit did not result in increased ADT abandonment. Only 13 percent of affected members abandoned an ADT drug altogether, compared with 15 percent in the control group.

"This study shows insurers can successfully implement safeguards to protect members from potentially harmful drug interactions," said Patrick Gleason, PharmD, Prime's Director of Clinical Outcomes Assessment. "Through the use of this safety edit, many patients were able to avoid potential heart complications that would require further medical treatment and unnecessary medical costs."

The published study abstract can be found in the Journal of Managed Care Pharmacy 2011;17(3):255. http://www.amcp.org/amcp.ark?c=jmcp&sc=articles&year=2011&volume=17&issue=3

Prime Therapeutics is a pharmacy benefit management company dedicated to providing innovative, clinically-based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to nearly 17 million covered lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered in St. Paul, Minnesota, Prime Therapeutics is collectively owned by 12 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at www.primetherapeutics.com.


'/>"/>
SOURCE Prime Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Medstreaming Launches Fully Integrated Cardiovascular PACS and Certified EMR With Electronic Whiteboard at ACC
2. Select Data Delivers on the Promise of a True Electronic Medical Record
3. Quest Diagnostics Launches National Electronic Health Records Awareness Tour Showcasing Care360 EHR
4. Nottingham University Hospital is First U.K. User of Elektas Electronic Medical Record Workspace for Image Guided Radiation Therapy
5. Reportlinker Adds EMR 2011: The Market for Electronic Medical Record Systems
6. Royal Fornia Electronic Device Co., Ltd. Signs Technology Licensing Agreement to Integrate Masimo rainbow SET Pulse CO-Oximetry Into New Patient Monitors
7. Allscripts Demonstrates Native Integration of Acute and Ambulatory Electronic Health Records at HIMSS
8. University Hospitals Selects Allscripts Electronic Health Record for 1,400 Physicians and Expands Sunrise™ Enterprise Acute Care EHR in Eight Hospitals
9. Reportlinker Adds Telemedicine: Opportunities for Medical and Electronic Providers
10. Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record
11. The SSI Group to Provide Health Care Providers with BNY Mellons Electronic Payment Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , Jan. 16, 2017  Cumberland Pharmaceuticals Inc. (NASDAQ: ... Kenneth J. Krogulski , CFA to its Board of ... of Berkshire Asset Management LLC . He is ... independent SEC registered investment advisory firm with over $1.5 ... 37 years, experience in security analysis and portfolio management. ...
(Date:1/14/2017)... Jan. 14, 2017  Johnson & Weaver, LLP announces that ... of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ) ... 31, 2016 (the "Class Period"). Zimmer Biomet provides ... orthopaedic reconstructive products, such as knee and hip reconstructive products. ... According ...
(Date:1/13/2017)... January 13, 2017 According ... and Equipment Market by Method (Biochemical (Calcium Phosphate, ... Protein Production), End User - Global Forecast to ... global market from 2016 to 2021. This market ... 2021 from USD 715.4 Million in 2016, at ...
Breaking Medicine Technology:
(Date:1/15/2017)... ... January 15, 2017 , ... ... Outreach is a program that strives to better communities around the world by ... community. It also provides the opportunity for team members to become involved in ...
(Date:1/15/2017)... ... January 15, 2017 , ... San Francisco Magazine recently ... Area counties for 2017. Almost 1,000 nominations were submitted and a little over ... Results were announced the magazine’s January 2017 issue . , Under the ...
(Date:1/14/2017)... ... January 14, 2017 , ... Healthy living ... line of activated charcoal products. With more and more people opting to go ... according to how they cater to specific needs. , Moody Zook focused particularly ...
(Date:1/13/2017)... ... 13, 2017 , ... People with type 2 diabetes know ... easy as checking the nutrition label on foods for grams of sugar. But ... sugar-free, proteins can influence — either positively or negatively — insulin secretion and ...
(Date:1/13/2017)... ... , ... With the increasing public preference for chemical-free personal ... alternatives for customers who have grown more conscious about maintaining their health and ... charcoal products, Moody Zook Chief Executive Officer Nate Ginsburg explained their company’s decision ...
Breaking Medicine News(10 mins):